Rain Therapeutics Inc. updated on its anticipated near-term milestones: Milademetan MDM2-Amplified Phase 2 Basket Trial (MANTRA-2): Phase 2 trial anticipated to commence enrollment this quarter; Interim data anticipated in the second half of 2022. Milademetan MCC Phase 2 Trial (MANTRA-3): Phase 2 trial anticipated to commence in mid-2022. Milademetan Dedifferentiated Liposarcoma Phase 3 Trial (MANTRA): Data anticipated in 2023. RAD52 Research Program: Lead candidate selection anticipated in 2022 .